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AED-efficacy and outcome measurements for effectiveness: 
evaluation of anti-epileptic drugs in the different phases of development
Introduction
A workshop was held in the Netherlands in which 
members from several commissions of the 
International League Against Epilepsy, its Dutch chap­
ter and invited experts participated.
Participants of this workshop are:
* Members of the ILAEcommission on Antiepileptic Drugs: E.
Beghi, P.de Bittencourt, D. Chadwick, O. Dulac, T.
Johnson, F. Pisani, R. Porter, D. Schmidt.
* Members of the ILAE Commission on Outcome 
Measurement: G.A. Baker, P. Camfield, J.A. Cramer,
A. Martins da Silva, H. Meinardi, E. Perucca.
* Members of the Dutch Commission on Antiepileptic 
Drugs: P.M. Edelbroek, Y.A. Hekster, j. Hulsman,
D.G.A. Kasteleijn-Nolst Trenité, B. vd Kley, J.W.A.
Meijer, J. Oostlng.
* Guest Experts: G.J. de Haan, C. Pachlatko, J.A.P. Van 
Parys, A.F.A.M, Schobben, S. Schwabe, S. Walker.
The goal of the workshop was to highlight and dis­
cuss the different aspects of outcome parameters and 
study designs and to formulate subsequent recom­
mendations. Working groups discussed issues of the 
pre-registration phase of AED-development with 
emphasis on questions such as monitoring of side 
effects, improvement of the profile of efficacy of the 
new drug before and after registration, and determi­
nation of the effect of the new drugs on the fetus. A 
debate of clinical outcome measures, with emphasis 
on the post-registration phase, addressed questions 
such as: what should be monitored and how; what is 
the relationship between knowledge concerning clini­
cal outcome measurements in the pre- and post-reg­
istration phase, and what is the impact of higher costs 
of the drugs? One of the issues was when to start 
monotherapy trials. Furthermore the validity and use 
of health-related quality of life scales in clinical prac­
tice and in drug development was discussed; should 
the scales involve both subjective and objective infor­
mation? Also the ethical issues with respect to devel­
opment and costs of new drugs were reviewed.
The papers presented during the Symposium to 
initiate discussions, a summary of the debate, and the 
recommendations, are published in this volume.
The organisers of this Symposium thank the editors of 
PWS for this opportunity.
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